[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353587-105":59,"doc-detail-353587-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","rubcn-as-a-novel-prognostic-biomarker-and-therapeutic-target-in-breast-cancer-research-article","RUBCN as a novel prognostic biomarker and therapeutic target in breast cancer - Research Article","","Analysis of autophagy-related gene expression data identifies RUBCN as a novel biomarker linked to breast cancer pathogenesis and progression, supporting its potential as a therapeutic target. Bioinformatics analyses across multiple public datasets build and validate a consensus prognostic model associated with patient outcomes. RUBCN expression is confirmed in cell lines and clinical tissues using Western blotting, qRT-PCR, and immunohistochemistry. Functional studies show RUBCN knockdown suppresses proliferation and invasion, and disrupts autophagic flux, with chloroquine-modulated LC3/P62. Pathway and enrichment results indicate RUBCN promotes progression via cell cycle and invasion regulation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/rubcn-as-a-novel-prognostic-biomarker-and-therapeutic-target-in-breast-cancer-research-article/353587/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/rubcn-as-a-novel-prognostic-biomarker-and-therapeutic-target-in-breast-cancer-research-article/353587.png","ImageObject",300,407,{"name":92,"@type":93},"Emma Wilson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How was RUBCN identified in the study?","Question",{"text":112,"@type":113},"RUBCN was identified from autophagy-related gene expression data and multiple breast cancer datasets using bioinformatics tools and databases.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the researchers validate RUBCN expression?",{"text":117,"@type":113},"RUBCN expression was verified in breast cancer cell lines and clinical tissue specimens using Western blotting, qRT-PCR, and immunohistochemistry.",{"name":119,"@type":110,"acceptedAnswer":120},"What effects did RUBCN knockdown have on breast cancer cells?",{"text":121,"@type":113},"RUBCN knockdown suppressed breast cancer cell proliferation and invasion and impaired autophagic flux, reflected in altered LC3 and P62 levels with chloroquine treatment.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353587,1790167655,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":81,"preview_urls":146},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","OPEN ACCESS  \nCitation: Yang DD, Liu CH, Jia SQ, Xue ZK, Zhang MM, Yang R, et al. (2026) RUBCN asa novel prognostic biomarker and therapeutic target in breast cancer. PLoS One 21(1): e0341357. [https://doi.org/10.1371/journal](https://doi.org/10.1371/journal). pone.0341357  \nEditor: Amy McCart Reed, The University of Queensland Faculty of Medicine, AUSTRALIA Received: August 29, 2025  \nAccepted: January 6, 2026  \nPublished: January 27, 2026  \nPeer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: [https://doi.org/10.1371/journal](https://doi.org/10.1371/journal). pone.0341357  \nCopyright: © 2026 Yang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution,  \nRESEARCH ARTICLE  \nRUBCN as a novel prognostic biomarker and therapeutic target in breast cancer  \nDong Dong Yang1☯, Cheng Hao Liu1☯, Sheng Qiu Jia1, Ze Kuan Xue1, Ming Ming Zhang2, Rui Yang3, Yong Zhou Huang4, Xin Chun Zhao4, Bao San Han5,6, Sheng Dong Nie7, Gui Lin Huang1,4*, Ji Xue Hou1,4*  \n1 School of Medicine, Shihezi University, Shihezi, China, 2 Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China, 3 Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 4 Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Shihezi University, Shihezi, China, 5 Department of Breast Surgery, Xinhua Hospital Affiliated of Shanghai Jiao Tong University School of Medicine, Shanghai, China, 6 Research Center of Breast Tumor Intelligent Diagnosis and Treatment, University of Shanghai for Science and Technology, Shanghai, China, 7 University of Shanghai for Science and Technology, School of Health Science and Engineering, Shanghai, China  \n☯ These authors contributed equally to this work.  \n* [15559016883@163.com](15559016883@163.com) (GLH); [hjx1506@163.com](hjx1506@163.com) (JXH)  \nAbstract  \nAnalysis of autophagy-related gene expression data identified RUBCN as a novel biomarker influencing the pathogenesis and progression of breast cancer, underscoring its potential as a therapeutic target. We analyzed multiple breast cancer sample datasets using bioinformatics tools and databases. A consensus prognostic model was constructed and validated across several independent datasets to further examine its association with patient outcomes. A series of bioinformatics analyses focused on RUBCN were conducted, including expression profiling, independent prognostic evaluation, immune correlation analysis, and survival analysis. RUBCN expression was verified in breast cancer cell lines and clinical tissue specimens via Western blotting, quantitative real-time reverse transcription PCR, and immunohistochemistry. Functional assays, such as the Cell Counting Kit-8 assay, 5-ethynyl-2’-deoxyuridine incorporation assay, wound healing assay, and Transwell invasion assay, were employed to evaluate the effects of RUBCN knockdown on breast cancer cell proliferation and invasion. Autophagic activity, indicated by LC3 and P62 levels, was measured via Western blot in RUBCN-knockdown breast cancer cells with or without chloroquine treatment. Elevated expression of multiple autophagy-related genes was observed in breast cancer. The consensus prognostic model accurately predicted survival across multiple datasets, with RUBCN emerging as a key gene whose expression levels were significantly correlated with patient prognosis. Enrichment analysis indicated that RUBCN likely promotes breast cancer progression by regulating cell cycle and invasion processes. Further investigation revealed a negative  \nPLOS One | [htt","cbCaitBdRndtqLUj","https://ap.wps.com/l/cbCaitBdRndtqLUj","pdf",4314344,22,"English","# Abstract","[{\"question\":\"How was RUBCN identified in the study?\",\"answer\":\"RUBCN was identified from autophagy-related gene expression data and multiple breast cancer datasets using bioinformatics tools and databases.\"},{\"question\":\"How did the researchers validate RUBCN expression?\",\"answer\":\"RUBCN expression was verified in breast cancer cell lines and clinical tissue specimens using Western blotting, qRT-PCR, and immunohistochemistry.\"},{\"question\":\"What effects did RUBCN knockdown have on breast cancer cells?\",\"answer\":\"RUBCN knockdown suppressed breast cancer cell proliferation and invasion and impaired autophagic flux, reflected in altered LC3 and P62 levels with chloroquine treatment.\"}]","RUBCN as a novel prognostic biomarker and therapeutic target in breast cancer - Research Article | PDF",1790106185,55,[147,151,155],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/e2fe99d7e2f9636c209cc794145d58ac.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/f892d3585887ebcfb3e8649f2c583eb7.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/7d0d59588c9f459b428c2016398c8067.webp",981,1269]